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2 Fax: +1 416 974 9757.The glycosphingolipid globotriaosyl ceramide, (Gala1-4Galß1-4 glucosyl ceramide-Gb3) also known
as CD77 and the Pk blood group antigen, is bound by both verotoxins and by the HIV adhesin, gp120.
Gb3 plays an important receptor role in VT induced hemolytic uremic syndrome (HUS) and HIV
infection. The organization of glycolipids, including Gb3, into lipid rafts is central to both patholo-
gies. The fatty acid heterogeneity within the Gb3 lipid moiety plays a central role in assembly within
such ordered domains. Differential binding of verotoxins and gp120 to such Gb3 isoforms in model
and cell membranes indicates a signiﬁcant role in the eventual pathogenic outcome. HUS may pro-
vide the ﬁrst example whereby membrane Gb3 organization provides a predictor for tissue selective
in vivo pathology.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Cell membrane lipid domains
Organization of membrane glycosphingolipids, and subse-
quently other lipids and membrane proteins into non-uniform do-
mains has been an area of intense research interest leading to the
concept of cell membrane ‘lipid rafts’ [1,2]. These domains are cur-
rently deﬁned as nano-assemblies of sphingolipid, cholesterol and
GPI anchored proteins which ﬂuctuate on a subsecond time scale
[3]. This concept has suffered through a period of controversy
[4,5], centered on extrapolation from detergent resistance and
model membrane studies, but is now emerging as a valid paradigm
of physiological membrane structure [6–8] likely to prove of
increasing relevance, particularly in intracellular trafﬁc [9] and sig-
naling [10]. In this view, the cellular membrane lipid matrix is
likely to prove the dynamic frame on which much of the protein
tapestry is threaded.
Initial studies on viral budding from cultured polarized epithe-
lial cells showed a differential glycosphingolipid (GSL) distributionchemical Societies. Published by E
tute, Division of Molecular
ren, 555 University Avenue,
5993.
ood), bbinn@sickkids.ca (B.
on.branch@utoronto.ca (D.R.in apical vs basolateral membranes [11,12], resulting from lipid
sorting within the secretory pathway. This physically based lipid
sorting may provide a more widespread basis of intercellular mem-
brane trafﬁcking routes. Membrane heterogeneity by rafts is
thought to rely on the potential for selective lipid–lipid interaction.
For in vitro model membrane systems, this is illustrated by the ste-
rol-dependent phase separation of sphingolipids from the more
unsaturated glycerophospholipids, clearly established for many
years in model systems [13,14]. However model membranes do
not equate to normal cell membrane physiology and the cellular
correlates of the Lo (liquid ordered phase) and Ld (liquid disor-
dered) phase have not been established. Very recent work shows
that the degree of order in coalesced raft membranes of cells is
substantially lower than that observed in model membranes, lead-
ing to the suggestion that lipid-based phase segregation principles
cooperate with other lateral speciﬁcities, possibly chemical inter-
actions involving proteins, to laterally organize function [15].
Accordingly, ESR on cell plasma membrane suggests that the lipid
basis for membrane ordering is modulated by proteins to allow
coexistence of ordered and disordered domains [16]. Chemically
derived cell membrane vesicles can be cooled to separate into
Lo-like and Ld-like phases [7]. However in this context, the ordered
phase typically excludes prototypical lipid raft proteins (as do
model membrane lo phases [15,17]) and thus the physiological
signiﬁcance of an Lo phase in cells still remains unclear. As key
components of membrane lipid domains, the variable fatty acidlsevier B.V. All rights reserved.
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ceramide synthases [18], may provide a mechanism for regulating
their composition.2. Verotoxins and their GSL receptors
Verotoxins are a family of Escherichia coli derived AB5 subunit
toxins (also termed Shiga toxins or Shiga-like toxins) ﬁrst de-
scribed and so named for their select cytotoxic activity on vero
cells an African green monkey renal tubule epithelial cell line
[19]. When puriﬁed and characterized these toxins were found to
be largely indistinguishable from the AB5 toxin of Shigella dysente-
riae [20] and are therefore also known as Shiga toxins, Stx. Their
study became of mainstream importance following the pioneering
epidemiological work of Karmali et al. [21], showing that infection
with E. coli producing these toxins was strongly associated with the
subsequent development of the hemolytic uremic syndrome, a pre-
viously idiopathic nephropathy resulting from glomerular occlu-
sion and more frequently associated with young children than
adults. Verotoxins comprises a family of highly related toxin com-
prising primarily VT1 and VT2 which are 60% homologous at the
protein level. Additional variants of VT2 have been described but
these are infrequently isolated clinically. More signiﬁcant is per-
haps VT2e or pig edema disease toxin which is a pathogen of pigs
[22]. All the verotoxins bind to the glycolipid globotriaosyl cera-
mide, Gala1-4Galß1-4 Glucosyl ceramide (also termed CD77 or
the pk blood group antigen), except for molecular which binds
the next homologue in this series globotetraosyl ceramide, Gb4,
in addition to Gb3 [23]. The gala1-4gal disaccharide does not occur
in mammalian glycoproteins, (but is present in avian egg glycopro-
teins [24]). Deletion of Gb3 synthase renders mice completely
resistant to VT1 and VT2 [25]. Thus GSLs are the only functional
VT1/2 receptors.
Although the receptor binding speciﬁcity of VT2 is the same as
that of VT1, i.e., Gb3 is recognized, the binding afﬁnity for VT2 is
signiﬁcantly less than that of VT1 [26]. Despite this fact, infections
with VT2 producing E. coli are more frequently observed in associ-
ation with human disease then are those of VT1 alone. VT2 is
slightly less cytotoxic then VT1 in vitro [27]. Thus receptor binding
afﬁnity and cytotoxicity in cell culture are not the only compo-
nents which deﬁne in vivo pathology. Our studies are targeted to
determine whether Gb3 membrane organization provides a basis
for differential VT1 and VT2 activity.Fig. 1. Comparison of VT1 and VT2 binding to Gb3, galabiosyl ceramide and
admantylGb3. GSLs were separated by TLC and detected by orcinol chemical spray.
After blocking with gelatin, separate plates were incubated with 1 lg/mL VT1 or
VT2. Excess toxin was removed and bound VT1/VT2 detected by immunostaining.
VT1 binding to Gb3, Gb2 (galabiosyl ceramide, gala1-4gal ceramide) and adamant-
ylGb3 is similar. However, VT2 binds Gb2 in preference to Gb3 and generation of
adamantylGb3 from Gb3 markedly increases VT2 binding.3. Aglycone modulation of Gb3 receptor function
Although glycolipids are synthesized by a series of glycosyl
transferases which add sugars moieties from activated nucleotide
sugars to grow an oligosaccharide chain in a step-wise fashion,
the lipid moiety, i.e., the ceramide, is heterogeneous, primarily
within its fatty acid content. In mammalian cells, these fatty acids
range from C16 to C24 primarily, although longer chain species are
reported in some tissues. Only even carbon numbered fatty acids
are present and these can be unsaturated or hydroxylated. Since
glycolipids are lipid–sugar conjugates and the lipid ceramide moi-
ety is embedded within the phospholipid membrane bilayer, the
sugar sequence, particularly for the shorter carbohydrate se-
quences, are very close to the plane of the plasma membrane. This
hydrophobic milieu can have a strong inﬂuence on the hydrophilic
carbohydrate moiety. The term ‘aglycone modulation’ of GSL
receptor function has been used to describe this effect, which relies
not only the composition of the ceramide moiety itself, but also
composition of the surrounding lipid membrane microenviron-
ment. Thus membrane lipid organization in terms of lipid microdo-mains or lipid rafts may regulate the bioavailability of GSLs for
interaction.
Aglycone modulation of carbohydrate availability for ligand
binding was ﬁrst reported in terms of glycolipid substrates for gal-
actose oxidase when it was shown that while galactosyl ceramide
was effectively bound and oxidized, galactosyl glycerolipid was not
[28]. Subsequent studies where the binding of antibodies to glyco-
lipids within cell membranes or model membranes depended on
the fatty acid composition of the glycolipid were later reported
[29,30]. Further studies of microbial interaction with target cell
glycolipids often showed that the binding speciﬁcity was depen-
dent not only the carbohydrate sequence but also on the character
of the lipid moiety itself [31–33] (most often hydroxylation was re-
quired). These studies show that the regulation of lipid bound car-
bohydrate for recognition by exogenous ligands is more complex
than for glycoconjugate carbohydrate sequences, for example, on
proteins. The question is not one of crypticity whereby cell mem-
brane glycolipids can be masked by larger or other cell surface car-
bohydrates [34] or proteins, since these binding effects can be
demonstrated in simple GSL/cholesterol model membranes, but
rather one of some ‘allosteric’ mechanism where changes in the
structure in a distal part of the molecule result in alteration of
the conformation of the carbohydrate, to allow or restrict ligand
binding. However, while VT2e, modeling studies predict an effect
of the lipid moiety on the carbohydrate conformation of membrane
GSLs [33,35], such differences have been difﬁcult to fully verify by
structural approaches [36,37].
Verotoxin binding to Gb3 is depending on the terminal Gala1-
4Gal disaccharide, since galabiosyl ceramide is also bound. An
interesting difference between VT1 and VT2 is that VT2 binds gala-
biosyl ceramide in preference to Gb3 (Fig. 1). Furthermore, a rat
IgM monoclonal antiGb3 [38] does not bind galabiosyl ceramide.
Thus different ligands which bind Gb3 can have a distinct subspec-
iﬁcity. In addition, the structure of the Gb3 lipid moiety, particu-
larly the fatty acid, is crucial to deﬁning the carbohydrate
presentation for binding [39], i.e., solid phase, tlc plate, liposome,
ELISAs, monolayer ﬁlm – can all affect the relative binding
capacity.
This is most clearly illustrated in the comparison of the Gb3
binding of the various verotoxin variants. Initial studies comparing
VT1 and VT2c binding to Gb3 fatty acid isoforms within lecithin/
cholesterol containing solid phase supports showed that while
the binding of VT1 was increased as a function of fatty acid chain
length, primarily C16 to C22, VT2c binding was essentially re-
stricted to C18 fatty acid containing Gb3 [40]. VT2c is a relatively
rare clinical isolate [41]. Subsequent studies however, also showed
that VT1/Gb3 binding was distinct from that of VT2. VT1 binding
inhibited subsequent VT2/Gb3 binding but VT2 binding was unable
Fig. 2. Cell selective binding by VT2. Texas red labeled VT2 is preferentially bound
and internalized by a sub population of HeLa and vero cells. After 1 h at 37 C, VT2 is
bound and retrograde transported to the Golgi of a subset of the monolayer cells as
compared with the labelled rab6 Golgi marker, present in all cells.
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binding of a monoclonal anti Gb3 antibody. Later studies using
deoxy Gb3 analogues showed that VT1 and VT2 show distinct but
overlapping hydroxyl requirements within the Gb3 carbohydrate
moiety and that the monoclonal antiGb3 showed a hydroxyl
requirement more similar to that of VT2 than VT1 [42]. In surface
plasmon resonance studies VT2 binding afﬁnity was less than that
of VT1 but the off rate was also less, suggesting that VT2 forms a
more stable Gb3 complex [43]. In detergent resistant model mem-
branes VT1 binding to Gb3/cholesterol vesicles was fatty acid
dependent in that C18 and C20 Gb3 was not recognized [44]. In
contrast, VT2 binding was independent of Gb3 fatty acid composi-
tion in this context.
The Gb3 binding site within the VT1B subunit pentamer was
ﬁrst proposed to lie within the inter-B subunit cleft [45]. This
was veriﬁed in molecular modeling studies which identiﬁed this
site as the potential primarily Gb3 binding site, but also identiﬁed
a second energy minimum more closely opposed to the surface of
the pentamer which would oppose the cell membrane when bound
[46]. Co-crystal studies using the VT1 B subunit pentamer and the
lipid free Gb3 oligosaccharide, showed that this second site was
primarily bound by the Gb3 oligosaccharide and that the inter-sub-
unit cleft site (site 1) was signiﬁcantly, but less frequently occupied
[47]. A third site comprised solely of trp 34 was also seen to bind
Gb3 sugar. Only site 2 binding of oligosaccharide was veriﬁed by
NMR [48] but sites 1 and 2 have been considered the primary
mechanism of verotoxin/Gb3 glycolipid binding [49]. Mutations
in both sites have shown their importance but some mutations
in site 1 which severely reduce cell binding/cytotoxicity had no ef-
fect on site 2 Gb3 oligosaccharide binding [50]. Verotoxin binding
to the Gb3 carbohydrate is very much reduced for the lipid-free su-
gar [51] but this can be compensated by appropriate steric multi-
meric presentation [52]. Site 2 is compromised as deﬁned by the
crystal structure of VT2 [53], suggesting that the different utility
of these two sites within these two toxins may be related to the
differential Gb3 glycolipid binding.
The differential cytotoxicity of VT1 and VT2 is reﬂected in vivo.
There is no small animal model of HUS, due to the fact that Gb3 is
absent from the renal glomerulus of rodents. In mice, there is a
remarkable difference between the in vivo susceptibility to VT1
and VT2. Although Gb3 deﬁcient mice are completely resistant to
both VT1 and VT2 [25], wild-type mice are approximately 400
times more sensitive to VT2 [54]. This correlates with a differential
distribution of VT1 and VT2 binding sites within mouse tissue [55].
For example, only VT1 binds to Gb3 located within the lung. Since
this induces no lung pathology, it can be considered as a VT1 bind-
ing ‘sink’ which competes for VT1 binding to more susceptible tis-
sues. Gb3 synthesis in endothelial cells can be increased by
treatment with cytokines and a mouse model for HUS was pro-
posed by pretreating with LPS to induce cytokines and upregulate
murine renal glomerular Gb3 synthesis [56]. Although a useful
model, the glomerular pathology in this model appears to be med-
iated by renal tubular VT1 Gb3 binding [57]. Renal glomerular Gb3
expression is restricted to primates and the only accurate HUS
model remains that of the baboon [58].
In a subset of adult human renal samples, differential glomeru-
lar binding of VT1 and VT2 was demonstrated [42]. Coincident VT2
and Mab antiGb3 glomerular staining was seen without VT1 bind-
ing. Cholesterol extraction of such glomeruli resulted in the induc-
tion of VT1 glomerular binding [42], indicating that excess
cholesterol could block Gb3 to prevent VT1, but not VT2 (or Mab
antiGb3) recognition. Some adult renal glomeruli were negative
for both VT1 and VT2 staining and cholesterol extraction induced
both VT1 and VT2 glomerular binding [59]. Thus membrane cho-
lesterol can mask Gb3 from binding both VT1/VT2 or VT1
preferentially.The differential binding of VT1 and VT2 to common and distinct
epitopes within the Gb3 glycolipid oligosaccharide [42] is reﬂected
in the plasma membrane binding of these toxins to target cells
[27]. The simultaneous labeling of vero cells with differentially la-
beled VT1 and VT2 at 4 C shows both overlapping and distinct
VT1/VT2 bound Gb3 assemblies [27]. These distinct and overlap-
ping domains are maintained during the early stages of internaliza-
tion such that VT2 undergoes retrograde transport largely via a
transferrin receptor containing vesicular route, whereas VT1 is lar-
gely excluded from transferrin containing vesicles. Both toxins coa-
lesce by retrograde transport in the Golgi and then migrate to the
ER (where a fraction of the A subunits separate and translocates to
the cytosol [60]) followed by a second separation phase as ﬁrst
VT1, followed by VT2 transits to more distal elements of the ER
and the nuclear envelope. Intracellular and cell surface bound
VT1 is more resistant to detergent extraction than is VT2, suggest-
ing that a greater proportion of VT1 bound Gb3 is within lipid rafts
as compared to VT2 [27].
In in vitro constructed Gb3/cholesterol containing detergent
resistant membranes, the optimum composition for VT1 and
VT2 binding is distinct. Higher levels of cholesterol inhibit VT1,
but not VT2 binding and sphingomyelin can augment the binding
of VT2 but not that of VT1 [27]. In addition VT1, but not VT2,
binding to these Gb3 DRM constructs was dependent on the Gb3
fatty acid content [44]. Thus VT1 and VT2 bind overlapping but
distinct Gb3 lipid assemblies both in model membrane systems
and within cell membranes. Interestingly, VT2 preferentially binds
Gb2, in which the galactose a1-4 galactose disaccharide is directly
linked to the ceramide lipid base [61], as compared to the more
common Gb3 (Fig. 1). Neither VT1 or VT2 show any binding to
Gb4, the next homologue in the globoGSL series (although if the
terminal GalNAc of Gb4 is deacetylated, strong binding is seen
[46]).
The differential character of VT1 and VT2 Gb3 binding is further
reﬂected in cell binding by the fact that not all vero cells are bound
by VT2. This may be a cell cycle dependence but within a culture,
cells which preferentially bind VT2 can be distinguished. Fig. 2
shows the internalization of VT2 within such a population of vero
and HeLa cells. It is clear that a fraction of the cell population can
be refractory to VT2 binding, internalization and retrograde trafﬁc
to the Golgi (monitored by rab6 staining). Preferential binding of
distinct Gb3 domains by VT2 mediates the differential intracellular
routing to the Golgi by VT2 as compared to VT1 [27]. The differen-
tial routing may be responsible for a novel VT2 selective pathology
observed for a sub-population of VT2 treated vero cells [27]. Vero
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vesicular vacuolization process 2–3 h after toxin administration.
The vacuoles are acidic and although not induced by VT1, prior
treatment with VT1 protects against subsequent VT2 induced vac-
uolation. This previously undescribed VT2 induced vacuolation
was prevented by inhibition of retrograde transport by brefeldin
A and occurred when most VT2 was found in the Golgi. The role
of this VT2 selective cell pathology in VT2 induced disease has
yet to be established, but clearly demonstrates differential Gb3
dependent cytopathology. A single cell membrane glycolipid can
therefore provide a differential receptor for different binding
ligands.
Although the Gb3 fatty acid modiﬁes VT1 binding, we have gen-
erated a soluble inhibitor of VT1/Gb3 binding by removing the fatty
acid of Gb3 and replacing it with a rigid adamantane hydrocarbon
frame [62]. This surprisingly water soluble conjugate, unlike the li-
pid-free Gb3 oligosaccharide [51], retains high afﬁnity VT1 and VT2
binding and protects cells in culture from both VT1 and VT2 cyto-
toxicity [27]. AdamantylGSLs retain the receptor function of the
parental GSL [63–65], suggesting that they mimic the membrane
presentation of GSLs in solution. For VT2, adamantylGb3 is bound
in preference to native Gb3 (Fig. 1), a clear example of aglycone
modulation of GSL receptor function. However, adamantylGb3
was not protective, but rather enhanced VT2 pathology in vivo
[55], possibly due to its amphipathic character which might allow
adamantylGb3 to insert into membranes and act as a pseudo recep-
tor for VT. Similar NBD-Gb3 analogues where the fatty acid is
substituted by a ﬂuorescent aromatic group, can partition into
the cell plasma membrane and bind verotoxin [66].4. Gb3 in DRMs
The maintenance of glycolipids within lipid rafts as monitored
by susceptibility to detergent extraction, may be complex, involv-
ing more than just the nature of the lipid moiety of the glycosphin-
golipid. Studies showing that the depletion of glucosyl ceramide
resulted in the loss of Gb3 from the detergent resistance membrane
fraction [67] imply that glycolipid/glycolipid interactions may be
necessary to resist detergent extraction. Recent studies showing
that speciﬁcally the C16 fatty acid isoform of glucosyl ceramide
was required for Gb3-bound VT1 to transit from endosomes to
the Golgi [68] may indicate that this interaction is also dependent
on the character of the lipid moiety.
VT1 ligation of cell membrane Gb3 within DRMs results in
trans-membrane signaling and activation of Src family kinases.
The retrograde transport of the verotoxin/Gb3 complex from the
cell surface to endosomes, to TGN, Golgi and ER is dependent on
the initial Gb3 being present within DRMs [69]. This retrograde
pathway is required for A subunit cytosolic transit [60] and hence
cytotoxicity. For cells in which Gb3 is present in the non-DRM plas-
ma membrane fraction, the toxin receptor complex is internalized
and trafﬁcked to lysosomes where the toxin is degraded and cells
therefore survive without cytotoxic effect [69]. Thus not all Gb3
containing cells are sensitive to VT cytotoxicity. This provides a
possible explanation as to why bovine animal reservoir gastroin-
testinal mucosal epithelial cells, which express Gb3 are neverthe-
less resistant to cytotoxicity [70]. Non-DRM Gb3 is in effect,
protective against VT. This may provide the explanation as to
why the Fabry mouse, which has increased levels of Gb3 within
many tissues, is resistant, rather than highly susceptible to
verotoxin [71]. A-subunit translocation into the cytosol from the
ER is also dependent on Gb3 within a DRM format [67]. This
raises questions as to the basis of such intracellular Gb3 containing
DRMs, since cholesterol concentrations within the ER are extre-
mely low.5. Gb3 detergent resistance is crucial for in vivo VT pathology
Although the interpretation of detergent resistant membranes
isolated from cells is complex, it is clear that detergent resistance
reﬂects a stronger lateral interaction between membrane compo-
nents and that this correlates with dynamic processes [72]. While
most GSLs are enriched in DRMs, it is clear that Gb3 can be found in
both the DRM and non-DRM fraction [67,69]. As with cytotoxicity,
VT1-induced transmembrane signaling also requires a Gb3 DRM
format [73,74]. We used this tool in intact tissues as a novel means
to dissect the Gb3 mediated, verotoxin induced pathology of HUS
[59], and found that Gb3 membrane organization plays a central
role in determining in vivo sensitivity to VT. HUS is primarily a dis-
ease of endothelial cells within the glomeruli (glomerular podo-
cytes and mesangial cells may also be involved) [75], however
Gb3 is distributed throughout the human nephron, highly ex-
pressed on tubular epithelial cells [76]. Thus, the basis of the glo-
merular selectivity of VT-induced HUS pathology is unknown.
Since VT1 cell cytotoxicity in vitro has been shown to depend on
Gb3 being present within DRMs [69], we investigated whether this
property could be used to probe Gb3 organization in the human
kidney. We found that renal tubular VT1/VT2 bound Gb3 is com-
pletely susceptible to brief detergent extraction at 4 C. In contrast,
VT1 and VT2 staining of renal glomeruli was entirely resistant to
similar detergent extraction [59]. In fact, glomerular VT1/VT2 bind-
ing to Gb3 was, according to sample, slightly, to signiﬁcantly en-
hanced in frozen adult renal sections after detergent extraction.
Thus, the Gb3 organization within the membrane of cells within
the glomerulus is completely distinct from that of the tubular epi-
thelial cells. Only glomerular Gb3 is detergent resistant and,
extrapolating from the cell culture results, this would predict that
only glomerular Gb3 containing cells will be sensitive to the cyto-
pathology of systemic VT1/VT2. This therefore provides a unique
explanation for the cell selectivity of the pathology of HUS and pro-
vides the ﬁrst clear example where the membrane organization a
glycosphingolipid receptor provides the main discriminator for
pathology in vivo.6. Role of Gb3 in HIV infection
6.1. Gp120–Gb3 binding
In addition to its role as the receptor mediating the pathology of
verotoxins, Gb3 is one of several GSLs involved in HIV infection. The
surface envelope glycoprotein, gp120 is the mechanism by which
the virus targets lymphoid cells for infection. Gp120 binds to
CD4 on T cells and monocytes and this induces a conformational
change to expose the V3 loop which subsequently binds to chemo-
kine co-receptor, either CXCR4 for T-tropic HIV strains or CCR5 for
R5 tropic strains, which are responsible for the sexual transmission
of HIV infection. The V3 loop also contains a GSL binding motif [77]
to which several glycolipids, galactosyl ceramide, sulfogalactosyl
ceramide, GM3, GD3 and Gb3 adhere [78–81]. GalCer binding by
gp120 has been strongly implicated as the mechanism of HIV tar-
geting and entry into CD4 negative cells, such as mucosal epithelial
cells [79,82,83].
Gp120 binding to Gb3/cholesterol DRM vesicles and Gb3 mono-
layers showed a similar dependence on the Gb3 fatty acid moiety
as VT1 [44]. C16, C22, C24 Gb3 vesicles were bound but C18 and
C20 were not recognized and, as for VT1, and these fatty acid iso-
forms were dominant negative for gp120 binding to Gb3 fatty acid
mixtures [44]. Again as for VT1, inclusion of C24:1Gb3 induced
strong gp120 binding, although this isoform alone binds VT1 and
gp120 poorly. This was most dramatically illustrated by the lack
of gp120 binding to C18 and C24:1Gb3 separately, but strong
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fatty acid isoforms can thus interact laterally within the bilayer to
modulate presentation for ligand binding. Although VT1 and gp120
showed a similar binding speciﬁcity for Gb3 fatty acid isoforms
within model membrane DRMs, when gp120 and VT1 were com-
pared for Gb3 binding within the human renal nephron [59], dis-
tinct differences were observed. As for VT1, gp120 binding to
tubular epithelial cells was within the detergent sensitive fraction.
VT1 binding competed for gp120 binding in these cells. Although
VT1 showed strong detergent resistant binding to renal glomeruli,
no glomerular binding was observed for gp120 [59]. Thus in this
tissue, gp120 may preferentially bind Gb3 within the non-DRM
fraction. The recombinant gp120 used in these studies is however
monomeric, unlike the trimeric presentation on the viral mem-
brane, so gp120 and gp120-mediated viral Gb3 binding may be
different.7. Gb3 and HIV infection-friend or foe?
Gb3 was initially reported to promote HIV infection in cultured
cells transfected with CD4 which remained insensitive to infection,
or to CD4 expressing cells in which the GSL complement had been
depleted [84,85].
These studies led to our investigation of the binding of gp120 to
adamantylGb3, the soluble Gb3 mimic which, unlike the lipid-free
glycan [51], retains high afﬁnity verotoxin binding [62]. The bind-
ing of HIV gp120 to Gb3 and adamantylGb3 was compared using a
monolayer surface balance [63]. Gp120 showed sigmoidal binding
kinetics to Gb3 monolayers. However, gp120 binding to adamant-
ylGb3 was exponential and far more rapid. Gp120 binding to Gb3
reached equilibrium only within hours, whereas the binding to
adamantylGb3 was saturated within 10 min. The binding of
gp120 to Gb3 was augmented in the presence of cholesterol to be-
come exponential. AdamantylGb3 may thus provide a soluble Gb3
mimic within the context of a cholesterol complex. Because of
the high afﬁnity binding of gp120 to adamantylGb3, we tested
the effect of adamantylGb3 on HIV infection of cultured and pri-
mary lymphoid target cells in vitro [86]. AdamantylGb3 proved
an effective inhibitor of HIV infection both for the X4 (T cell-tropic)
and R5 (monocyte tropic) laboratory strains of HIV. In addition,
adamantylGb3 was an effective inhibitor of infection by HIV strains
which were resistant to other therapeutic drugs. In a cell culture
model system in which HIV gp120 and gp41 were expressed in
one cell type and CD4 and chemokine receptor expressed in an-
other, adamantylGb3 was found to act as an inhibitor of HIV-host
cell membrane fusion. AdamantylGb3 inhibition of infection was
observed, even for an HIV strain resistant to the only fusion inhibi-
tion (T20) approved for clinical use.
The fact that Gb3 might prove a resistance factor rather than
promote HIV infection was ﬁrst suggested by our studies exam-
ining the HIV susceptibility of target lymphocytes from Fabry pa-
tients. In Fabry disease there is an increased level of Gb3 due to
a defect in the a-galactosidase responsible for the catabolism of
Gb3. Peripheral blood mononuclear cells (PBMCs) were found to
be resistant to R5 HIV infection in vitro [87], but PBMC sensitiv-
ity to X4 HIV remained unaffected. We argued that this was
likely due to the fact that monocytes normally express Gb3
and therefore would accumulate Gb3 in Fabry disease whereas
T cells do not express Gb3 (though Gb3 expression was detected
for PHA/IL2 activated T-cells [86]) such that Gb3 would be there-
fore unlikely to accumulate in Fabry CD4 positive T cells. How-
ever the level of CCR5 chemokine receptor was reduced in the
Fabry PBMCs such that the mechanism of protection might be
due to increased Gb3 preventing the cell surface expression of
CCR5.The potential of Gb3 as a lymphoid resistance factor against HIV
infection was more thoroughly examined by studying the HIV sus-
ceptibility of PBMCs from different subgroups within the P blood
group system [88]. The P blood group system is a minor blood
group based on the expression of globo series glycolipids [89].
Globotetraosyl ceramide, Gb4, is the P antigen while Gb3 is Pk.
Members of the rare p blood group have no functional a-galactosyl
transferase (Gb3 synthase) and therefore express no Gb3. The
equally rare P1k blood group individuals have a defect in the ß1-
4GalNac transferase which converts Gb3 into Gb4 and therefore
accumulate the Gb3 precursor GSL. PBMCs from p individuals were
found to show far higher susceptibility to HIV infection in vitro
than ‘normal’ (P blood group) individuals. This difference could
be up to 1000-fold. In contrast, PBMCs from individuals of the
P1k blood group were up to 50 times more resistant to HIV infec-
tion in vitro than P blood group PBMCs. These differences were ob-
served for both X4 and R5 HIV1 strains. These changes in HIV
susceptibility did not correlate with any changes in the surface
expression of CD4 or chemokine co-receptor. In HIV susceptible
HeLa cells transfected with CD4, we showed that HIV susceptibility
was inversely proportional to the Gb3 concentration. Gb3 was
selectively increased by transfection with Gb3 synthase while siR-
NA against Gb3 synthase was used to selectively deplete HeLa cells
of their Gb3 content. Fusion of the Gb3 negative Jurkat T cell line
with liposomes containing Gb3 resulted in signiﬁcant inhibition
of subsequent HIV susceptibility whereas fusion with Gb4 lipo-
somes had no signiﬁcant effect. In the Gb3 positive human lym-
phoid cell line THP1, susceptible to X4 HIV1 infection, in vitro
pharmacological manipulation of cellular Gb3 levels also demon-
strated an inverse relationship between Gb3 levels and HIV suscep-
tibility [90]. The a-galactosidase inhibitor deoxygalactonijirimycin
[91] was used to increase the Gb3 content of THP1 cells while the
glucosyl ceramide synthase inhibitor, P4 [92] was used to deplete
THP1 cells of their Gb3 content. Similar results were obtained for
the R5 HIV1 susceptible U87G astrocytoma cell line transfected
with CD4 [90].
Although yet to be proven, it may be that the membrane orga-
nization of Gb3 within lipid domains deﬁnes the activity in HIV
infection. Gb3 within lipid DRMs may promote HIV infection/mem-
brane fusion whereas non-DRM Gb3 may counter HIV infection.
Although gp120 binds to several glycolipids and the glycolipid
binding motif has been identiﬁed in the V3 loop [77], it is not clear
how or whether different glycolipids binding within this site could
have differential effects. Thus GalCer binding can actively promote
viral host cell fusion whereas Gb3 appears to inhibit it. The glyco-
lipid binding site XXXGPGRAFXXX [93] within the V3 loop is in the
center of the chemokine receptor binding domain S/
GXXXGPGXXXXXXXE/D [94] and thus glycolipid binding should
in fact, inhibit subsequent chemokine receptor binding by the
same V3 loop domain. CD4 binding by gp120 is required to open
the V3 loop to allow subsequent chemokine receptor binding
[95]. Gp120 glycolipid binding does not require prior recognition
of CD4. However soluble CD4 can increase gp120 GSL interaction
[96]. Gp120 binding to Gb3/cholesterol vesicles is enhanced in
the presence of soluble CD4 [97]. This is consistent with V3 loop
binding by gp120 in that this domain becomes more exposed –
which facilitates Gb3 binding–following CD4 recognition. However,
unlike for the chemokine receptor, signiﬁcant glycolipid binding is
observed prior to CD4 binding by gp120. This is consistent with the
smaller molecular size of Gb3 compared to chemokine receptor.
Treatment of gp120 with the soluble Gb3 mimic, adamantyl Gb3,
or a soluble Gb3 mimic based on Gb3 oligosaccharide coupled to
phosphatidyl ethanolamine (FSL-Gb3 [98]) shows that gp120 bind-
ing to Gb3 mimics prevents gp120 binding to Gb3 and to GalCer and
(less effectively) to sulfatide (Fig. 3), formally showing that these
glycolipids share a common binding site on gp120. It may be that
Fig. 3. Gp120 binding to GSL cholesterol vesicles. GSL cholesterol vesicles were
generated [44] and immobilized on nitrocellulose. After blocking, the nitrocellulose
strips were incubated with R5 gp120 (3 lg/mL) overnight and after washing, bound
gp120 detected by immunostaining. Panels A–C Vesicles equivalent to 50, 25 and
5 lg GSL (from the top) were dot blotted on each nitrocellulose panel and tested for
gp120 binding. The effect of preincubation of gp120 with 300 lM adamantylGb3
(panel B) or FSL Gb3 (soluble Gb3 mimic based on PE [99]) (panel C) on GSL binding
was compared. The inhibitory effect of the soluble Gb3 mimics on gp120/GSL vesicle
binding was quantitated in panel D, using Image J software. Sulfatide (SGC) showed
the strongest gp120 binding, followed by GalCer and then Gb3. No binding to
cholesterol alone or Gb4/cholesterol vesicles was detected. The soluble Gb3 mimics
inhibited gp120 binding to Gb3 and GalCer and, to a lesser extent, to SGC.
1884 C.A. Lingwood et al. / FEBS Letters 584 (2010) 1879–1886the size of the carbohydrate determines the effect, with the smaller
galactosyl ceramide facilitating gp120 chemokine receptor binding
whereas the larger Gb3 binding in the same site may inhibit the
same chemokine receptor-gp120 interaction.
It is clear that all membrane globotriaosyl ceramide is not cre-
ated equal. The lipid heterogeneity will result in differential lateral
cell membrane organization with cholesterol and other lipids to af-
fect receptor and intracellular trafﬁcking functions. This aglycone
modulation of receptor function may be a dynamic process as
Gb3 (plus ligand) trafﬁcks intracellularly to membranes of different
lipid composition.
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